LID.L Regulatory News (LID)

21 Apr 2008 07:00

LiDCO Group Plc21 April 2008 Press Release 21 April 2008 LiDCO Group Plc ("LiDCO" or the "Company") Launch of new LiDCOrapid Monitor First Sales to Europe and the USA New Market Opportunity LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, announcesthat its new surgery product, the LiDCOrapid Monitor, has now been released forsale in Europe and the USA. Dr Terry O'Brien, LiDCO's CEO, commented: "I am pleased to announce that thefirst shipments of our new easy-to-use surgery product - the LiDCOrapid Monitor- are now on the way to customers in the USA and Europe. This follows finalregulatory clearance. "This new product opens a much bigger market opportunity for LiDCO. Oursuccessful LiDCOplus monitor is now widely used in Intensive Care Units forhigh-risk cardiovascular and shock patients. Our new LiDCOrapid monitor istargeted at use in the Operating Theatre, where many more times as many patientsare treated. Both products share the favourable attributes of not only reducingcomplications but also saving costs. "We have had excellent feedback from the pre-launch clinical user group who havebeen using the LiDCOrapid in major surgery patients in the UK and USA. We alsohad a very favourable reaction when the product was previewed at twointernational congresses - the World Congress of Intensive Care, Cape Town, andthe ESICM meeting in Brussels. At these meetings alone we took around 500 salesleads. This positive customer response to our new easy-to-use hemodynamicmonitor confirms our initial impressions: there is a great appetite for use ofthe LiDCOrapid in order to reduce surgical complications. I am delighted thatour direct sales staff and our growing distributor network can now begin tocapitalise on this exciting global market opportunity." The LiDCOrapid Monitor is an ideal new tool for acute care fluid and drugmanagement, facilitating the efficient delivery of goal-directed management(GDM) strategies directly at the point of care in the operating theatre. Itincorporates LiDCO's proprietary, patented and clinically validated PulseCOalgorithm. The new monitor features many clinical benefits. These enable acute carephysicians to get accurate and immediate feedback on the patient's fluid andhemodynamic status - a key measure of overall well-being during and aftersurgery. • Early and rapid warning of change • Clear indication of therapeutic route: fluid or drug • Quantification of hemodynamic response, particularly stroke volume • Permits more effective delivery of fluids - the right amount at the right time • Contributes to reduced morbidity and complications, notably infections • Reduces length of stay • Reduces overall cost of care As previously announced, LiDCO's preliminary results will be disseminated onThursday, 24 April 2008. An analyst briefing will now be taking place at theoffices of Abchurch Communications, LiDCO's new PR advisor, at 100 CannonStreet. London EC4N 6EU at 09:30am. If you are interested in attending thebriefing, please contact Abchurch on 020 7398 7700. - ENDS - For more information please contact: LiDCO Group Plc www.LiDCO.co.uk Terry O'Brien, Chief Executive Tel: +44 (0)20 7749 1500 John Rowland, Company Secretary Media enquiries Abchurch Communications www.abchurch-group.com Heather Salmond / Stephanie Cuthbert Tel: +44 (0) 207 398 7718 Stephanie.cuthbert@abchurch-group.com About LiDCO Group Plc LiDCO is a leading supplier of minimally invasive hemodynamic monitoringequipment and disposables. These are used primarily for the management ofhospital patients requiring critical care or at major cardiovascular risk.LiDCO's computer-based technology significantly reduces the complications(particularly infections) and costs associated with major surgery. Thetechnology was invented in the Department of Applied Physiology based at StThomas' Hospital, London. LiDCO is based in the UK and its shares are traded onAIM. For more information please see www.lidco.com. The Company's manufacturing facility is in Hoxton, London and its currentproducts are: * LiDCOplus and PulseCO monitors: these computer-based platforms are used in theIntensive Care Unit for real-time continuous display of hemodynamic parametersincluding cardiac output, oxygen delivery and fluid volume (PPV% and SVV%) * LiDCO disposables: used in conjunction with the LiDCOplus Monitor for accuratemeasurement of cardiac output in a minimally invasive manner * LiDCOview: an easy-to-use graphical display of historical LiDCOplushemodynamic data. Both clinical researchers and routine users can viewbeat-to-beat hemodynamic data collected with the LiDCOplus. LiDCOviewSE is thestandard version of this tool and is available for free, allowing anyone todownload and access data from the LiDCOplus. LiDCOviewPRO is the Professionalversion, allowing users to analyse, export and report the LiDCOplus data. A freetrial of LiDCOviewPRO is available for evaluation purposes prior to purchase * LiDCOlive: a software product in development for the remote display ofhemodynamic monitoring parameters derived through use of the LiDCOplus orLiDCOrapid monitors * LiDCOrapid : our new cardiac output monitor designed specifically for use inthe Operating Theatre for fluid and drug management at the point of care Distribution Network: The Company has now achieved registration of its products in 14 markets inEurope, the USA, Brazil, South Korea and Japan. It sells direct in the UK andUSA, and elsewhere through a worldwide network of speciality critical care andanesthesia distributors. This information is provided by RNS The company news service from the London Stock Exchange